数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James E. Davis Chairman, Chief Executive Officer and President 61 1267.38万美元 7.48 2024-04-05
Wright L. Lassiter III Director 60 30.04万美元 未持股 2024-04-05
Luiz A. Diaz, Jr. Director 53 28.04万美元 未持股 2024-04-05
Gary M. Pfeiffer Director 74 34.21万美元 未持股 2024-04-05
Timothy M. Ring Director 66 34.59万美元 未持股 2024-04-05
Denise M. Morrison Director 70 31.23万美元 0.29 2024-04-05
Vicky B. Gregg Director 69 31.57万美元 1.36 2024-04-05
Timothy L. Main Director 67 31.54万美元 2.09 2024-04-05
Tracey C. Doi Director 63 30.04万美元 未持股 2024-04-05

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James E. Davis Chairman, Chief Executive Officer and President 61 1267.38万美元 7.48 2024-04-05
Mark E. Delaney Senior Vice President and Chief Commercial Officer 56 未披露 未持股 2024-04-05
Mark A. Gardner Senior Vice President, Molecular Genomics and Oncology 58 未披露 未持股 2024-04-05
Karthik Kuppusamy Senior Vice President, Clinical Solutions 54 201.52万美元 0.95 2024-04-05
Patrick Plewman Senior Vice President, Diagnostics Services 57 197.99万美元 未持股 2024-04-05
Sam A. Samad Executive Vice President and Chief Financial Officer 54 397.51万美元 0.41 2024-04-05
Michael J. Deppe -- Senior Vice President, Corporate Controller and Chief Accounting Officer -- 未披露 未持股 2024-04-05
Catherine T. Doherty Senior Vice President, Regional Businesses 61 315.88万美元 6.48 2024-04-05
Michael E. Prevoznik Senior Vice President and General Counsel 62 225.19万美元 3.85 2024-04-05

董事简历

中英对照 |  中文 |  英文
James E. Davis

James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。


James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions. He initially managed a portfolio of businesses and was instrumental in refocusing the Company on diagnostic information services. Mr. Davis was given positions of increasing responsibility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。
James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions. He initially managed a portfolio of businesses and was instrumental in refocusing the Company on diagnostic information services. Mr. Davis was given positions of increasing responsibility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
Wright L. Lassiter III

Wright L. Lassiter III是亨利·福特医疗系统(Henry Ford Health System)的总裁兼首席执行官,该系统位于密歇根州,由六家医院,一项医疗计划以及一系列门诊,零售和相关医疗服务组成。 Lassiter先生于2014年12月加入亨利·福特健康系统,担任总裁,并于2016年出任首席执行官。在加入亨利·福特健康系统之前,他于2005年至2014年担任加利福尼亚州奥克兰Alameda保健系统的首席执行官。目前担任芝加哥联邦储备银行董事局副主席,主持其治理和提名委员会,并担任其审计委员会成员。他还是亨利·福特医疗系统和几个非营利组织的董事会成员,包括底特律投资局,勒莫因学院,莫敦博物馆,底特律市中心合伙企业和底特律地区商会。 Lassiter先生在美国医疗保健系统方面拥有广泛的执行经验,包括治理,战略规划,市场扩展,并购,绩效改善和公司扭亏为盈。


Wright L. Lassiter III,In August 2022, Mr. Lassiter became Chief Executive Officer of CommonSpirit Health, one of the country's largest and most diverse health care organizations, with a network of 140 hospitals and more than 1,500 care sites across 21 states. Prior to joining CommonSpirit Health, he was President and Chief Executive Officer of Henry Ford Health System in Detroit, Michigan from December 2014 to 2022. Prior to that, he was Chief Executive Officer of Alameda Health System in Oakland, California from 2005 to 2014. Mr. Lassiter currently serves on the board of Fortive Corporation and is the Chair of the American Hospital Association. Previously he served on the boards of DT Midstream, Inc. from 2021 to 2023 and Henry Ford Health System and as Vice Chair for the Federal Reserve Bank of Chicago.
Wright L. Lassiter III是亨利·福特医疗系统(Henry Ford Health System)的总裁兼首席执行官,该系统位于密歇根州,由六家医院,一项医疗计划以及一系列门诊,零售和相关医疗服务组成。 Lassiter先生于2014年12月加入亨利·福特健康系统,担任总裁,并于2016年出任首席执行官。在加入亨利·福特健康系统之前,他于2005年至2014年担任加利福尼亚州奥克兰Alameda保健系统的首席执行官。目前担任芝加哥联邦储备银行董事局副主席,主持其治理和提名委员会,并担任其审计委员会成员。他还是亨利·福特医疗系统和几个非营利组织的董事会成员,包括底特律投资局,勒莫因学院,莫敦博物馆,底特律市中心合伙企业和底特律地区商会。 Lassiter先生在美国医疗保健系统方面拥有广泛的执行经验,包括治理,战略规划,市场扩展,并购,绩效改善和公司扭亏为盈。
Wright L. Lassiter III,In August 2022, Mr. Lassiter became Chief Executive Officer of CommonSpirit Health, one of the country's largest and most diverse health care organizations, with a network of 140 hospitals and more than 1,500 care sites across 21 states. Prior to joining CommonSpirit Health, he was President and Chief Executive Officer of Henry Ford Health System in Detroit, Michigan from December 2014 to 2022. Prior to that, he was Chief Executive Officer of Alameda Health System in Oakland, California from 2005 to 2014. Mr. Lassiter currently serves on the board of Fortive Corporation and is the Chair of the American Hospital Association. Previously he served on the boards of DT Midstream, Inc. from 2021 to 2023 and Henry Ford Health System and as Vice Chair for the Federal Reserve Bank of Chicago.
Luiz A. Diaz, Jr.

Luiz A. Diaz, Jr.,自2016年12月起担任Memorial Sloan Kettering Cancer Center实体肿瘤学部门主管。此前,他是约翰霍普金斯大学医学院的教员和医生。他创立了几家生物技术公司,包括Epitope, Inostics, PapGene (Thrive)和Personal Genome Diagnostics, Inc.。Diaz博士的早期工作为Quest Diagnostics提供了第一个明确的证据,将循环肿瘤DNA作为筛选、监测和检测隐匿性疾病的癌症生物标志物。他在错配修复缺陷肿瘤患者中发现了免疫疗法与癌症遗传学之间的治疗联系,这导致了美国食品药品监督管理局(FDA)首次批准了对这种遗传病变的肿瘤进行肿瘤诊断,并于2022年发表了第一项癌症研究,结果100%完全缓解率。Diaz博士从2017年起担任Jounce Therapeutics, Inc.的董事会成员,直到该公司于2023年被收购。他获得了许多奖项和荣誉。Diaz博士于2023年当选为美国国家医学院院士,并于2021年被拜登总统任命为美国国立卫生研究院国家癌症咨询委员会成员。


Luiz A. Diaz, Jr.,has been the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc. Dr. Diaz's early work provided the first definitive evidence for Quest Diagnostics Incorporated ing circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors, which led to the first tumor agnostic FDA approval for tumors with this genetic lesion and the first cancer study, published in 2022, that resulted in a 100% complete remission rate. Dr. Diaz served on the board of Jounce Therapeutics, Inc. from 2017 until it was acquired in 2023. He is the recipient of numerous awards and honors. Dr. Diaz was elected to the National Academy of Medicine in 2023 and in 2021 he was appointed by President Biden to the National Cancer Advisory Board of the National Institutes of Health.
Luiz A. Diaz, Jr.,自2016年12月起担任Memorial Sloan Kettering Cancer Center实体肿瘤学部门主管。此前,他是约翰霍普金斯大学医学院的教员和医生。他创立了几家生物技术公司,包括Epitope, Inostics, PapGene (Thrive)和Personal Genome Diagnostics, Inc.。Diaz博士的早期工作为Quest Diagnostics提供了第一个明确的证据,将循环肿瘤DNA作为筛选、监测和检测隐匿性疾病的癌症生物标志物。他在错配修复缺陷肿瘤患者中发现了免疫疗法与癌症遗传学之间的治疗联系,这导致了美国食品药品监督管理局(FDA)首次批准了对这种遗传病变的肿瘤进行肿瘤诊断,并于2022年发表了第一项癌症研究,结果100%完全缓解率。Diaz博士从2017年起担任Jounce Therapeutics, Inc.的董事会成员,直到该公司于2023年被收购。他获得了许多奖项和荣誉。Diaz博士于2023年当选为美国国家医学院院士,并于2021年被拜登总统任命为美国国立卫生研究院国家癌症咨询委员会成员。
Luiz A. Diaz, Jr.,has been the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc. Dr. Diaz's early work provided the first definitive evidence for Quest Diagnostics Incorporated ing circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors, which led to the first tumor agnostic FDA approval for tumors with this genetic lesion and the first cancer study, published in 2022, that resulted in a 100% complete remission rate. Dr. Diaz served on the board of Jounce Therapeutics, Inc. from 2017 until it was acquired in 2023. He is the recipient of numerous awards and honors. Dr. Diaz was elected to the National Academy of Medicine in 2023 and in 2021 he was appointed by President Biden to the National Cancer Advisory Board of the National Institutes of Health.
Gary M. Pfeiffer

Gary M. Pfeiffer ,他于2006年退任杜邦公司(E.I. DuPont de Nemours & Co.) 的高级副总裁兼首席财务官。他于1974年加入杜邦,并负责杜邦及其子公司的金融和国际业务。从2009年1月至6月,他担任特拉华州的财政部秘书。从2005年到2012年,他担任英特奈普网络服务公司的董事,以及塔尔伯特公司的董事。他是特拉华州健康中心的董事会的非执行主席,以及Green tech Capital Advisors公司的咨询委员会成员。2004年12月以来,他一直担任奎斯特诊断公司(Quest Diagnostics)的董事。


Gary M. Pfeiffer,retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer served as a director of Internap Corporation from 2007 to 2020, TerraVia Holdings, Inc. from 2014 to 2017 and Talbots, Inc. from 2005 to 2012. He served as the non-executive Chair of the Board of Directors of Christiana Care Health System, a regional hospital system located in Delaware, from 2012 to 2016.
Gary M. Pfeiffer ,他于2006年退任杜邦公司(E.I. DuPont de Nemours & Co.) 的高级副总裁兼首席财务官。他于1974年加入杜邦,并负责杜邦及其子公司的金融和国际业务。从2009年1月至6月,他担任特拉华州的财政部秘书。从2005年到2012年,他担任英特奈普网络服务公司的董事,以及塔尔伯特公司的董事。他是特拉华州健康中心的董事会的非执行主席,以及Green tech Capital Advisors公司的咨询委员会成员。2004年12月以来,他一直担任奎斯特诊断公司(Quest Diagnostics)的董事。
Gary M. Pfeiffer,retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer served as a director of Internap Corporation from 2007 to 2020, TerraVia Holdings, Inc. from 2014 to 2017 and Talbots, Inc. from 2005 to 2012. He served as the non-executive Chair of the Board of Directors of Christiana Care Health System, a regional hospital system located in Delaware, from 2012 to 2016.
Timothy M. Ring

Timothy M. Ring担任C. R. Bard公司的董事长和首席执行官。Mr. Ring 自2003年8月担任公司董事长和首席执行官,从1997年4月至2003年8月担任集团总裁,在1993年12月至1997年12月担任集团副总裁,从1992年至1993年担任人力资源总裁。他还担任Quest Diagnostics Incorporated的董事。Mr. Ring为CIT集团有限公司的前董事。Mr. Ring是执行委员会成员。Mr. Ring因其先前在董事会工作超过20年,在C. R. Bard有多种领导经验,包括公司董事长和首席执行官,使得其符合董事会要求。 他此前负责公司的全球导管和专业访问业务。Mr. Ring是 has been instrumental in developing and implementing C. R. Bards目前发展和实施器材战略指导。在加入公司之前,他在Abbott Laboratories收获了人力资源和管理方面的宝贵经验。 Mr. Ring是新泽西州牙医科学及药品大学基金会托管人。他在康奈尔大学获得产业与劳动关系理学学士学位。


Timothy M. Ring,is Quest Diagnostics Incorporated Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.
Timothy M. Ring担任C. R. Bard公司的董事长和首席执行官。Mr. Ring 自2003年8月担任公司董事长和首席执行官,从1997年4月至2003年8月担任集团总裁,在1993年12月至1997年12月担任集团副总裁,从1992年至1993年担任人力资源总裁。他还担任Quest Diagnostics Incorporated的董事。Mr. Ring为CIT集团有限公司的前董事。Mr. Ring是执行委员会成员。Mr. Ring因其先前在董事会工作超过20年,在C. R. Bard有多种领导经验,包括公司董事长和首席执行官,使得其符合董事会要求。 他此前负责公司的全球导管和专业访问业务。Mr. Ring是 has been instrumental in developing and implementing C. R. Bards目前发展和实施器材战略指导。在加入公司之前,他在Abbott Laboratories收获了人力资源和管理方面的宝贵经验。 Mr. Ring是新泽西州牙医科学及药品大学基金会托管人。他在康奈尔大学获得产业与劳动关系理学学士学位。
Timothy M. Ring,is Quest Diagnostics Incorporated Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.
Denise M. Morrison

Denise M. Morrison 是Denise Morrison & Associates, LLC(咨询公司)的创始人。她于2018年退休,担任Campbell Soup Company的总裁和首席执行官。她于2003年加入Campbell,担任越来越重要的职位。在加入Campbell之前,她从2001年到2003年在Kraft Foods, Inc.担任行政管理职务。她是MetLife, Inc.和Visa, Inc.的董事,2010年至2018年担任Campbell Soup Company的董事,2005年至2010年担任The Goodyear Tire & Rubber Company的董事。她是波士顿学院(Boston College)、商业委员会和Just Capital咨询委员会的董事会成员。她曾任职于塔夫茨弗里德曼营养科学与政策学院的顾问委员会;新泽西重启和恢复委员会;特朗普总裁的制造业就业计划;以及奥巴马总裁的出口委员会。


Denise M. Morrison,is the founder of Denise Morrison & Associates, LLC, a consulting firm. She retired in 2018 as the President and Chief Executive Officer of Campbell Soup Company. Ms. Morrison joined Campbell in 2003, where she held positions of increasing responsibility. Prior to joining Campbell, she held executive management positions at Kraft Foods, Inc. from 2001 to 2003. Ms. Morrison is a director of MetLife, Inc. and Visa, Inc. and served as a director of Campbell Soup Company from 2010 to 2018 and a director of The Goodyear Tire & Rubber Company from 2005 to 2010. She is a member of the Board of Trustees for Boston College, the Business Council and the Advisory Council for Just Capital. Ms. Morrison previously served on the Advisory Board for Tufts Friedman School of Nutrition Science and Policy; the New Jersey Restart and Recovery Commission; President Trump's Manufacturing Jobs Initiative; and President Obama's Export Council.
Denise M. Morrison 是Denise Morrison & Associates, LLC(咨询公司)的创始人。她于2018年退休,担任Campbell Soup Company的总裁和首席执行官。她于2003年加入Campbell,担任越来越重要的职位。在加入Campbell之前,她从2001年到2003年在Kraft Foods, Inc.担任行政管理职务。她是MetLife, Inc.和Visa, Inc.的董事,2010年至2018年担任Campbell Soup Company的董事,2005年至2010年担任The Goodyear Tire & Rubber Company的董事。她是波士顿学院(Boston College)、商业委员会和Just Capital咨询委员会的董事会成员。她曾任职于塔夫茨弗里德曼营养科学与政策学院的顾问委员会;新泽西重启和恢复委员会;特朗普总裁的制造业就业计划;以及奥巴马总裁的出口委员会。
Denise M. Morrison,is the founder of Denise Morrison & Associates, LLC, a consulting firm. She retired in 2018 as the President and Chief Executive Officer of Campbell Soup Company. Ms. Morrison joined Campbell in 2003, where she held positions of increasing responsibility. Prior to joining Campbell, she held executive management positions at Kraft Foods, Inc. from 2001 to 2003. Ms. Morrison is a director of MetLife, Inc. and Visa, Inc. and served as a director of Campbell Soup Company from 2010 to 2018 and a director of The Goodyear Tire & Rubber Company from 2005 to 2010. She is a member of the Board of Trustees for Boston College, the Business Council and the Advisory Council for Just Capital. Ms. Morrison previously served on the Advisory Board for Tufts Friedman School of Nutrition Science and Policy; the New Jersey Restart and Recovery Commission; President Trump's Manufacturing Jobs Initiative; and President Obama's Export Council.
Vicky B. Gregg

Vicky B. Gregg,Ms. Gregg在2012年12月从田纳西BlueCross BlueShieldd公司的总裁、首席执行官和主管位置上退休。BCBST是非营利组织,与其子公司,提供全方位的集团和个人健康保险计划、产品和服务。她自2003年担任BCBST的职务。在担任总裁和首席执行官之前,Ms. Gregg担任BCBST公司的总裁和首席执行官,负责公司的日常运营。Ms. Gregg在一家上市公司Team健康有限公司担任主管。她自2011年担任First Horizon的主管。 Ms. Gregg独立于在纽交所上市的标准,担任审计委员会金融407(d)(5)项定义S-K SEC的监管专家。此外,她作为审计委员金融专家的额外信息和背景经验,在第12页签署的委托书上证明她领导审计金融委员会。Ms. Gregg 多种健康医疗背景,包括:临床护理,医院信息,长期护理,医疗福利和资金。她执行经验在医疗卫生产业提供了专业处理卫生保健,医疗资金的丰富经验,可以运营大型公司,包括金融和审计、公司管理、人员雇佣、收购并购、风险资产、公民事务和政府关系。作为田纳西的居民,她的知识适用于田纳西市场,侧重银行核心业务。她在众多非营利组织和贸易组织董事会担任职务,过去几年里,她被选为田纳西政府圆桌会议的专员。


Vicky B. Gregg,is a cofounder/partner of Guidon Partners LLC. She retired as Chief Executive Officer of Blue Cross Blue Shield of Tennessee in 2012. Prior to becoming Chief Executive Officer in 2003, Ms. Gregg served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg served as a member of the U.S. National Institutes of Health Commission on Systemic Interoperability. She currently serves on the boards of Acadia Healthcare Company, Inc., Erlanger Health System and the Electric Power Board of Chattanooga, as well as the boards of several private companies, including MyEyeDr. Previously, Ms. Gregg served on several boards, including TeamHealth Holdings, Inc., then a public company, from 2013 to 2017 and First Horizon Corporation from 2011 to 2015. She has also served as Chair of America's Health Insurance Plans, as a member of the BlueCross BlueShield Association, as Chair of the Board of the National Institute for Healthcare Management, and as a member of the Healthcare Leadership Council.
Vicky B. Gregg,Ms. Gregg在2012年12月从田纳西BlueCross BlueShieldd公司的总裁、首席执行官和主管位置上退休。BCBST是非营利组织,与其子公司,提供全方位的集团和个人健康保险计划、产品和服务。她自2003年担任BCBST的职务。在担任总裁和首席执行官之前,Ms. Gregg担任BCBST公司的总裁和首席执行官,负责公司的日常运营。Ms. Gregg在一家上市公司Team健康有限公司担任主管。她自2011年担任First Horizon的主管。 Ms. Gregg独立于在纽交所上市的标准,担任审计委员会金融407(d)(5)项定义S-K SEC的监管专家。此外,她作为审计委员金融专家的额外信息和背景经验,在第12页签署的委托书上证明她领导审计金融委员会。Ms. Gregg 多种健康医疗背景,包括:临床护理,医院信息,长期护理,医疗福利和资金。她执行经验在医疗卫生产业提供了专业处理卫生保健,医疗资金的丰富经验,可以运营大型公司,包括金融和审计、公司管理、人员雇佣、收购并购、风险资产、公民事务和政府关系。作为田纳西的居民,她的知识适用于田纳西市场,侧重银行核心业务。她在众多非营利组织和贸易组织董事会担任职务,过去几年里,她被选为田纳西政府圆桌会议的专员。
Vicky B. Gregg,is a cofounder/partner of Guidon Partners LLC. She retired as Chief Executive Officer of Blue Cross Blue Shield of Tennessee in 2012. Prior to becoming Chief Executive Officer in 2003, Ms. Gregg served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg served as a member of the U.S. National Institutes of Health Commission on Systemic Interoperability. She currently serves on the boards of Acadia Healthcare Company, Inc., Erlanger Health System and the Electric Power Board of Chattanooga, as well as the boards of several private companies, including MyEyeDr. Previously, Ms. Gregg served on several boards, including TeamHealth Holdings, Inc., then a public company, from 2013 to 2017 and First Horizon Corporation from 2011 to 2015. She has also served as Chair of America's Health Insurance Plans, as a member of the BlueCross BlueShield Association, as Chair of the Board of the National Institute for Healthcare Management, and as a member of the Healthcare Leadership Council.
Timothy L. Main

Timothy L. Main,自2013年1月,他担任董事长。他还在Quest Diagnostics公司担任董事。Quest Diagnostics公司致力于提供诊断信息服务。自2000年至2013年3月1日,他担任Jabil公司的首席执行官,并自1999年担任董事。他于1987年进入Jabil公司并担任生产管理经理,于1987年晋升为运营经理,于1989年晋升为项目经理,于1991年担任副总裁,负责业务开发事务,于1996年担任高级副总裁,负责业务开发事务,并于1999年晋升为总裁。在加盟Jabil公司前,他在底特律国家银行(National Bank of Detroit)的国际部担任商业贷款总监。他在密歇根州立大学(Michigan State University)获得学士学位,并在美国雷鸟全球管理学院(American Graduate School of International Management Thunderbird)获得国际管理学硕士学位。


Timothy L. Main,has been the Non-Executive Chairman of WNS (Holdings) Limited since September 2021. From 2000 until 2013 he was the Chief Executive Officer, and from 2013 until 2021 the non-executive Chairman of the Board, of Jabil, Inc., an electronic product solutions company providing comprehensive electronics design, manufacturing and management services to global electronics and technology companies. As Chief Executive Officer, Mr. Main led Jabil's growth strategy, increasing annual revenues nearly five-fold to reach $17 billion in 2012, and expanding in Asia and other emerging markets. He also served on the board of SCP & Co Healthcare Acquisition Company from 2021 to 2022.
Timothy L. Main,自2013年1月,他担任董事长。他还在Quest Diagnostics公司担任董事。Quest Diagnostics公司致力于提供诊断信息服务。自2000年至2013年3月1日,他担任Jabil公司的首席执行官,并自1999年担任董事。他于1987年进入Jabil公司并担任生产管理经理,于1987年晋升为运营经理,于1989年晋升为项目经理,于1991年担任副总裁,负责业务开发事务,于1996年担任高级副总裁,负责业务开发事务,并于1999年晋升为总裁。在加盟Jabil公司前,他在底特律国家银行(National Bank of Detroit)的国际部担任商业贷款总监。他在密歇根州立大学(Michigan State University)获得学士学位,并在美国雷鸟全球管理学院(American Graduate School of International Management Thunderbird)获得国际管理学硕士学位。
Timothy L. Main,has been the Non-Executive Chairman of WNS (Holdings) Limited since September 2021. From 2000 until 2013 he was the Chief Executive Officer, and from 2013 until 2021 the non-executive Chairman of the Board, of Jabil, Inc., an electronic product solutions company providing comprehensive electronics design, manufacturing and management services to global electronics and technology companies. As Chief Executive Officer, Mr. Main led Jabil's growth strategy, increasing annual revenues nearly five-fold to reach $17 billion in 2012, and expanding in Asia and other emerging markets. He also served on the board of SCP & Co Healthcare Acquisition Company from 2021 to 2022.
Tracey C. Doi

Tracey C. Doi,2011年8月起担任董事长。2003年起,她担任Toyota Motor Sales, U.S.A., Inc.(一家汽车公司,为丰田、雷克萨斯和后裔汽车的美国售营销和分销部门)副总裁和首席财务官。Doi女士主要负责公司财务、税务、海关、财政、会计、采购、行政服务。她Toyota Motor Sales审计委员会、风险委员会和福利委员会任职,同时也是几家Toyota Motor Sales替公司的董事长或负责人。她于2000年进入Toyota,担任副总裁和企业控制官,2003年晋升为首席财务官。此前,她在AT&T Wireless(一家无线通信公司)、 L.A.Cellular Telephone Company(一家无线通信公司)和L.A.Gear, Inc.(鞋业公司)担任财务管理职位。1983年,她获得UCLA商业经济学学士学位,是一位未在职的注册会计师。她现在是 Federal Reserve Bank of San Francisco经济顾问委员会成员、the Food Allergy Research & Education (FARE)董事会成员、the Japanese American National Museum理事会成员以及US-Japan Council董事会成员。


Tracey C. Doi,retired as Chief Financial Officer and Group Vice President of Toyota Motor North America, Inc. in 2022, after serving nearly twenty years as Chief Financial Officer. Ms. Doi joined Toyota in 2000 as Vice President, Corporate Controller and her responsibilities continued to expand upon her elevation to Chief Financial Officer in 2003. She currently serves on the board of Pentair plc and as an independent trustee of SunAmerica Series Trust and Season Series Trust. Ms. Doi served on the board of City National Bank, a Royal Bank of Canada Company, from 2016 to 2021, and on the Federal Reserve Bank of San Francisco Economic Advisory Council from 2009 to 2016. She is an active board member of the National Asian/Pacific Islander American Chamber of Commerce Foundation, National Association of Corporate Directors North Texas, 50/50 Women on Boards, International Women's Forum – Dallas and the Japanese American National Museum.
Tracey C. Doi,2011年8月起担任董事长。2003年起,她担任Toyota Motor Sales, U.S.A., Inc.(一家汽车公司,为丰田、雷克萨斯和后裔汽车的美国售营销和分销部门)副总裁和首席财务官。Doi女士主要负责公司财务、税务、海关、财政、会计、采购、行政服务。她Toyota Motor Sales审计委员会、风险委员会和福利委员会任职,同时也是几家Toyota Motor Sales替公司的董事长或负责人。她于2000年进入Toyota,担任副总裁和企业控制官,2003年晋升为首席财务官。此前,她在AT&T Wireless(一家无线通信公司)、 L.A.Cellular Telephone Company(一家无线通信公司)和L.A.Gear, Inc.(鞋业公司)担任财务管理职位。1983年,她获得UCLA商业经济学学士学位,是一位未在职的注册会计师。她现在是 Federal Reserve Bank of San Francisco经济顾问委员会成员、the Food Allergy Research & Education (FARE)董事会成员、the Japanese American National Museum理事会成员以及US-Japan Council董事会成员。
Tracey C. Doi,retired as Chief Financial Officer and Group Vice President of Toyota Motor North America, Inc. in 2022, after serving nearly twenty years as Chief Financial Officer. Ms. Doi joined Toyota in 2000 as Vice President, Corporate Controller and her responsibilities continued to expand upon her elevation to Chief Financial Officer in 2003. She currently serves on the board of Pentair plc and as an independent trustee of SunAmerica Series Trust and Season Series Trust. Ms. Doi served on the board of City National Bank, a Royal Bank of Canada Company, from 2016 to 2021, and on the Federal Reserve Bank of San Francisco Economic Advisory Council from 2009 to 2016. She is an active board member of the National Asian/Pacific Islander American Chamber of Commerce Foundation, National Association of Corporate Directors North Texas, 50/50 Women on Boards, International Women's Forum – Dallas and the Japanese American National Museum.

高管简历

中英对照 |  中文 |  英文
James E. Davis

James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。


James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions. He initially managed a portfolio of businesses and was instrumental in refocusing the Company on diagnostic information services. Mr. Davis was given positions of increasing responsibility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。
James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions. He initially managed a portfolio of businesses and was instrumental in refocusing the Company on diagnostic information services. Mr. Davis was given positions of increasing responsibility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
Mark E. Delaney

Mark E. Delaney,他于2022年3月加入公司,负责所有销售业务。从2017年到2021年Hill-Rom Holdings Inc.被Baxter Healthcare收购,他曾担任Hill-Rom(医疗保健行业医疗技术和相关服务的制造商和提供商)的销售和营销副总裁;被Baxter收购后,他担任Baxter的副总裁兼总经理,直到他加入Quest Diagnostics。此前,他曾在General Electric的医疗保健业务担任多个高级销售和营销领导职务,最近担任高级副总裁兼区域经理,负责成像、患者监测、信息技术和服务的区域销售。


Mark E. Delaney,joined the Company in March 2022 and is responsible for all sales operations. From 2017 until Hill-Rom Holdings Inc. was acquired by Baxter Healthcare in 2021, Mr. Delaney served as Vice President of Sales and Marketing at Hill-Rom, a manufacturer and provider of medical technologies and related services for the healthcare industry; after the acquisition by Baxter Mr. Delaney became Vice President and General Manager at Baxter until he joined Quest Diagnostics.Previously, Mr. Delaney served in a number of senior sales and marketing leadership roles at General Electric's healthcare business, most recently as Senior Vice President and Zone Manager, where he had regional responsibility for sales of imaging, patient monitoring, IT and services.
Mark E. Delaney,他于2022年3月加入公司,负责所有销售业务。从2017年到2021年Hill-Rom Holdings Inc.被Baxter Healthcare收购,他曾担任Hill-Rom(医疗保健行业医疗技术和相关服务的制造商和提供商)的销售和营销副总裁;被Baxter收购后,他担任Baxter的副总裁兼总经理,直到他加入Quest Diagnostics。此前,他曾在General Electric的医疗保健业务担任多个高级销售和营销领导职务,最近担任高级副总裁兼区域经理,负责成像、患者监测、信息技术和服务的区域销售。
Mark E. Delaney,joined the Company in March 2022 and is responsible for all sales operations. From 2017 until Hill-Rom Holdings Inc. was acquired by Baxter Healthcare in 2021, Mr. Delaney served as Vice President of Sales and Marketing at Hill-Rom, a manufacturer and provider of medical technologies and related services for the healthcare industry; after the acquisition by Baxter Mr. Delaney became Vice President and General Manager at Baxter until he joined Quest Diagnostics.Previously, Mr. Delaney served in a number of senior sales and marketing leadership roles at General Electric's healthcare business, most recently as Senior Vice President and Zone Manager, where he had regional responsibility for sales of imaging, patient monitoring, IT and services.
Mark A. Gardner

Mark A. Gardner,他于2022年10月加入公司担任现任职务。他负责肿瘤学、病理学、专业遗传学和研究与开发。Gardner先生从外科技术和工具提供商Corza Medical加入Quest,自2019年起担任欧洲商业运营和生物外科产品的执行合伙人、高级副总裁兼总经理。在此之前,他曾担任OmniSeq Corporation(分子诊断公司)的首席执行官(2016年至2019年),以及Thermo Fisher Scientific Inc.的副总裁兼总经理(2003年至2016年),包括在Life Technologies和Invitrogen的职位。他的职业生涯始于在麦肯锡公司担任顾问。


Mark A. Gardner,joined the Company in October 2022 in his current role. He is responsible for oncology, pathology, specialty genetics, and research and development. Mr. Gardner joined Quest from Corza Medical, a provider of surgical technologies and tools, where he served since 2019 as Executive Partner, Senior Vice President and General manager of European Commercial Operations and Biosurgery Products. Prior to that, Mr. Gardner served as Chief Executive Officer of OmniSeq Corporation, a molecular diagnostics company, from 2016 to 2019 and in Vice President and General Manager positions at Thermo Fisher Scientific Inc. from 2003 to 2016, including roles with Life Technologies and Invitrogen. He began his career as a consultant with McKinsey and Company, Inc.
Mark A. Gardner,他于2022年10月加入公司担任现任职务。他负责肿瘤学、病理学、专业遗传学和研究与开发。Gardner先生从外科技术和工具提供商Corza Medical加入Quest,自2019年起担任欧洲商业运营和生物外科产品的执行合伙人、高级副总裁兼总经理。在此之前,他曾担任OmniSeq Corporation(分子诊断公司)的首席执行官(2016年至2019年),以及Thermo Fisher Scientific Inc.的副总裁兼总经理(2003年至2016年),包括在Life Technologies和Invitrogen的职位。他的职业生涯始于在麦肯锡公司担任顾问。
Mark A. Gardner,joined the Company in October 2022 in his current role. He is responsible for oncology, pathology, specialty genetics, and research and development. Mr. Gardner joined Quest from Corza Medical, a provider of surgical technologies and tools, where he served since 2019 as Executive Partner, Senior Vice President and General manager of European Commercial Operations and Biosurgery Products. Prior to that, Mr. Gardner served as Chief Executive Officer of OmniSeq Corporation, a molecular diagnostics company, from 2016 to 2019 and in Vice President and General Manager positions at Thermo Fisher Scientific Inc. from 2003 to 2016, including roles with Life Technologies and Invitrogen. He began his career as a consultant with McKinsey and Company, Inc.
Karthik Kuppusamy

Karthik Kuppusamy于2022年8月担任现职。他负责公司除肿瘤学以外的临床专营权,以及公司的制药服务、基因组服务、医疗事务、医疗质量和全球市场活动。Kuppusamy先生担任包容性和多样性理事会的联合主席。此前,Kuppusamy先生自2018年起担任北区诊断信息服务业务副总裁兼总经理,并于2014年至2017年担任神经科特许经营和消费者遗传学总经理。他于2014年加入公司,此前任职于通用电气的医疗保健业务,在诊断影像事业部担任产品开发、研发、销售和营销总经理职务。


Karthik Kuppusamy,assumed his current role in August 2022. He is responsible for the following clinical franchises: Cardiovascular, Metabolic, Endocrinology and Wellness, Drug Monitoring and Toxicology, Infectious Disease and Immunology, Neurology, and Women's and Reproductive Health. He is also responsible for the Company's pharmaceutical services, genomic customer services, medical affairs, medical quality and regulatory. Mr. Kuppusamy serves as co-chair of the Company's Inclusion and Diversity Council. Previously, Mr. Kuppusamy was Vice President and General Manager of the Company's Diagnostics Information Services business in its North Region since from 2018 and General Manager of the Neurology Franchise and Consumer Genetics from 2014 to 2017. He joined the Company in 2014 from General Electric's healthcare business where he held general manager roles in product development, research and development, sales and marketing in the Diagnostics Imaging Division.
Karthik Kuppusamy于2022年8月担任现职。他负责公司除肿瘤学以外的临床专营权,以及公司的制药服务、基因组服务、医疗事务、医疗质量和全球市场活动。Kuppusamy先生担任包容性和多样性理事会的联合主席。此前,Kuppusamy先生自2018年起担任北区诊断信息服务业务副总裁兼总经理,并于2014年至2017年担任神经科特许经营和消费者遗传学总经理。他于2014年加入公司,此前任职于通用电气的医疗保健业务,在诊断影像事业部担任产品开发、研发、销售和营销总经理职务。
Karthik Kuppusamy,assumed his current role in August 2022. He is responsible for the following clinical franchises: Cardiovascular, Metabolic, Endocrinology and Wellness, Drug Monitoring and Toxicology, Infectious Disease and Immunology, Neurology, and Women's and Reproductive Health. He is also responsible for the Company's pharmaceutical services, genomic customer services, medical affairs, medical quality and regulatory. Mr. Kuppusamy serves as co-chair of the Company's Inclusion and Diversity Council. Previously, Mr. Kuppusamy was Vice President and General Manager of the Company's Diagnostics Information Services business in its North Region since from 2018 and General Manager of the Neurology Franchise and Consumer Genetics from 2014 to 2017. He joined the Company in 2014 from General Electric's healthcare business where he held general manager roles in product development, research and development, sales and marketing in the Diagnostics Imaging Division.
Patrick Plewman

Patrick Plewman于2022年4月担任现职。他负责一系列数据驱动的分析和服务,包括雇主Population Health、医疗保健分析解决方案、Pack Health、风险评估(ExamOne)和雇主解决方案。自2013年加入Quest Diagnostics Incorporated以来,Plewman先生自2018年起担任西部地区诊断信息服务业务的副总裁兼总经理,此前曾担任心血管、代谢和内分泌专营权总经理、传染病和免疫学专营权总经理以及General Health and Wellness专营权总经理。在加入Quest Diagnostics Incorporated之前,Plewman先生曾担任diaDexus公司的联合创始人、总裁和首席执行官。在此之前,Plewman先生曾在SmithKline Beecham公司担任多个职务,职责日益增加。


Patrick Plewman,assumed his current role in April 2022. He is responsible for a portfolio of data driven analytics and services offerings, including Employer Population Health, Healthcare Analytic Solutions, Pack Health, Risk Assessment (ExamOne) and Employer Solutions. Since joining the Company in 2013, Mr. Plewman was Vice President and General Manager of the Company's Diagnostic Information Services Business in its West Region since 2018 and previously served as General Manager of the Company's Cardiovascular, Metabolic and Endocrinology Franchise, General Manager of the Company's Infectious Disease and Immunology Franchise and General Manager of the General Health and Wellness franchise.Prior to joining the Company, Mr. Plewman served as Co-Founder, President and Chief Executive Officer of diaDexus, Inc. Previously, Mr. Plewman held various positions of increasing responsibility at SmithKline Beecham.
Patrick Plewman于2022年4月担任现职。他负责一系列数据驱动的分析和服务,包括雇主Population Health、医疗保健分析解决方案、Pack Health、风险评估(ExamOne)和雇主解决方案。自2013年加入Quest Diagnostics Incorporated以来,Plewman先生自2018年起担任西部地区诊断信息服务业务的副总裁兼总经理,此前曾担任心血管、代谢和内分泌专营权总经理、传染病和免疫学专营权总经理以及General Health and Wellness专营权总经理。在加入Quest Diagnostics Incorporated之前,Plewman先生曾担任diaDexus公司的联合创始人、总裁和首席执行官。在此之前,Plewman先生曾在SmithKline Beecham公司担任多个职务,职责日益增加。
Patrick Plewman,assumed his current role in April 2022. He is responsible for a portfolio of data driven analytics and services offerings, including Employer Population Health, Healthcare Analytic Solutions, Pack Health, Risk Assessment (ExamOne) and Employer Solutions. Since joining the Company in 2013, Mr. Plewman was Vice President and General Manager of the Company's Diagnostic Information Services Business in its West Region since 2018 and previously served as General Manager of the Company's Cardiovascular, Metabolic and Endocrinology Franchise, General Manager of the Company's Infectious Disease and Immunology Franchise and General Manager of the General Health and Wellness franchise.Prior to joining the Company, Mr. Plewman served as Co-Founder, President and Chief Executive Officer of diaDexus, Inc. Previously, Mr. Plewman held various positions of increasing responsibility at SmithKline Beecham.
Sam A. Samad

Sam A. Samad,他于2022年7月加入公司担任现任职务。他负责公司的财务、会计、投资者关系、内部审计和库务活动。加入公司之前,他曾担任Illumina, Inc. (DNA测序和基于阵列的技术的全球领导者)的首席财务官,2017年以来。加入Illumina之前,他在Cardinal Health担任多个高级领导职位,包括高级副总裁和财务主管,负责Cardinal Health中国业务的运营和财务责任,此前在Eli Lilly and Company担任国内和国际销售和财务职务。


Sam A. Samad,joined the Company in his current role in July 2022. He is responsible for the Company's finance, accounting, investor relations, internal audit and treasury activities. Prior to joining the Company, Mr. Samad served as Chief Financial Officer of Illumina, Inc., a global leader in DNA sequencing and array-based technologies, since 2017. Prior to joining Illumina, Mr. Samad held several senior leadership positions at Cardinal Health, including Senior Vice President and Treasurer, with operational and financial responsibility for Cardinal Health's China business, and before that in sales and finance roles at Eli Lilly and Company, both domestically and internationally.
Sam A. Samad,他于2022年7月加入公司担任现任职务。他负责公司的财务、会计、投资者关系、内部审计和库务活动。加入公司之前,他曾担任Illumina, Inc. (DNA测序和基于阵列的技术的全球领导者)的首席财务官,2017年以来。加入Illumina之前,他在Cardinal Health担任多个高级领导职位,包括高级副总裁和财务主管,负责Cardinal Health中国业务的运营和财务责任,此前在Eli Lilly and Company担任国内和国际销售和财务职务。
Sam A. Samad,joined the Company in his current role in July 2022. He is responsible for the Company's finance, accounting, investor relations, internal audit and treasury activities. Prior to joining the Company, Mr. Samad served as Chief Financial Officer of Illumina, Inc., a global leader in DNA sequencing and array-based technologies, since 2017. Prior to joining Illumina, Mr. Samad held several senior leadership positions at Cardinal Health, including Senior Vice President and Treasurer, with operational and financial responsibility for Cardinal Health's China business, and before that in sales and finance roles at Eli Lilly and Company, both domestically and internationally.
Michael J. Deppe
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Catherine T. Doherty

Catherine T. Doherty ,她是高级副总裁,负责临床特许经营。她负责监督临床特许经营解决方案的发展,涉及心血管、传染病和免疫学、神经学、处方药物监测和毒理学、妇女的健康和一般健康、以及企业范围的战略营销和业务发展。2014年2月,她负责为雇主提供解决方案,涉及医疗卫生信息技术和人寿保险公司服务业务。从2011年5月到2011年12月,她担任高级副总裁,负责医生服务。从2008年到2011年5月,她担任副总裁,负责医院服务。2008年之前,她于1990年加入该公司,并担任多种职务,包括副总裁,负责董事长办公室;副总裁,负责医院业务的财务和管理;副总裁,负责沟通和投资者关系;首席财务官。


Catherine T. Doherty,Since March 2022, Ms. Doherty has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization and marketing. She also is responsible for driving operational excellence, including the Company's quality and efficiency initiatives. Ms. Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network and was formerly co-chair of the Company's Inclusion and Diversity Council.From January 2020 to January 2023, she was responsible for consumer-initiated testing, which was launched under her leadership. From January 2013 to March 2022, Ms. Doherty was Senior Vice President and Group Executive - Clinical Franchise Solutions and Marketing. In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, the employer solutions and risk assessment businesses, and beginning in February 2020, Quest Diagnostics Incorporated sports diagnostics franchise. She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare IT business from February 2014 to January 2017.Prior to January 2013, Ms. Doherty held a variety of positions of increasing responsibility since joining the Company in 1990, including Senior Vice President, Physician Services; Vice President, Hospital Services; Vice President, Office of the Chairman; Vice President, Finance and Administration for the Hospital business; Vice President, Communications and Investor Relations; and Chief Accounting Officer.
Catherine T. Doherty ,她是高级副总裁,负责临床特许经营。她负责监督临床特许经营解决方案的发展,涉及心血管、传染病和免疫学、神经学、处方药物监测和毒理学、妇女的健康和一般健康、以及企业范围的战略营销和业务发展。2014年2月,她负责为雇主提供解决方案,涉及医疗卫生信息技术和人寿保险公司服务业务。从2011年5月到2011年12月,她担任高级副总裁,负责医生服务。从2008年到2011年5月,她担任副总裁,负责医院服务。2008年之前,她于1990年加入该公司,并担任多种职务,包括副总裁,负责董事长办公室;副总裁,负责医院业务的财务和管理;副总裁,负责沟通和投资者关系;首席财务官。
Catherine T. Doherty,Since March 2022, Ms. Doherty has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization and marketing. She also is responsible for driving operational excellence, including the Company's quality and efficiency initiatives. Ms. Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network and was formerly co-chair of the Company's Inclusion and Diversity Council.From January 2020 to January 2023, she was responsible for consumer-initiated testing, which was launched under her leadership. From January 2013 to March 2022, Ms. Doherty was Senior Vice President and Group Executive - Clinical Franchise Solutions and Marketing. In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, the employer solutions and risk assessment businesses, and beginning in February 2020, Quest Diagnostics Incorporated sports diagnostics franchise. She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare IT business from February 2014 to January 2017.Prior to January 2013, Ms. Doherty held a variety of positions of increasing responsibility since joining the Company in 1990, including Senior Vice President, Physician Services; Vice President, Hospital Services; Vice President, Office of the Chairman; Vice President, Finance and Administration for the Hospital business; Vice President, Communications and Investor Relations; and Chief Accounting Officer.
Michael E. Prevoznik

Michael E. Prevoznik,他是高级副总裁兼法律总顾问。他在1999年8月加入了公司,并担任副总裁兼总法律顾问。2003年,他负责政府事务。从1999年到2009年4月,他也负责公司的合规管理部门。2011年4月以来,除了担任总顾问,他担任管理职位,负责该公司在美国之外的诊断信息服务。此外,从2011年4月到2011年1月,他负责管理公司的临床试验业务。在加入公司之前,他担任史克必成( SmithKline Beecham )组织内部合规管理职位,相应责任也越来越大,最近担任合规副总裁,负责协调全球所有史克必成的合规活动。


Michael E. Prevoznik,joined the Company as Vice President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. Mr. Prevoznik also is the Executive Co-Sponsor of the Company's Quest for Health Equity Initiative.From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department. In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the United States, and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide.
Michael E. Prevoznik,他是高级副总裁兼法律总顾问。他在1999年8月加入了公司,并担任副总裁兼总法律顾问。2003年,他负责政府事务。从1999年到2009年4月,他也负责公司的合规管理部门。2011年4月以来,除了担任总顾问,他担任管理职位,负责该公司在美国之外的诊断信息服务。此外,从2011年4月到2011年1月,他负责管理公司的临床试验业务。在加入公司之前,他担任史克必成( SmithKline Beecham )组织内部合规管理职位,相应责任也越来越大,最近担任合规副总裁,负责协调全球所有史克必成的合规活动。
Michael E. Prevoznik,joined the Company as Vice President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. Mr. Prevoznik also is the Executive Co-Sponsor of the Company's Quest for Health Equity Initiative.From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department. In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the United States, and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide.